Literature DB >> 19841285

Accelarated skeletal maturation in children with primary hypertension.

Pawel Pludowski1, Mieczyslaw Litwin, Anna Niemirska, Maciej Jaworski, Joanna Sladowska, Edyta Kryskiewicz, Elzbieta Karczmarewicz, Joanna Neuhoff-Murawska, Aldona Wierzbicka, Roman S Lorenc.   

Abstract

It is hypothesized that primary hypertension (PH) is a disorder with origins in childhood linked to, at least in part, aberrations of growth and maturation processes. To evaluate the possible relation between the rate of biological maturity and development of PH, bone age (BA) assessments on the basis of dual x-ray absorptiometry-derived hand scans were performed in 54 newly diagnosed children and adolescents with PH and 54 healthy controls matched for body mass index (BMI), age and sex. Chronological age (CA), body height (in centimeters), body weight (in kilograms), BMI (in kilograms per meter squared), and blood pressure were assessed. Healthy controls had a mean BA of 14.7+/-2.3 years that was not significantly different from their mean CA of 14.2+/-2.1 years. In the PH group, the BA of 16.0+/-2.0 years was higher by 1.9+/-0.9 years compared with their CA of 14.1+/-2.0 years (P<0.0001). The magnitude of acceleration of skeletal maturation (BA-CA) and its prevalence (88.9%) were significantly higher in PH compared with BMI-matched controls (37.0%; chi(2)=31.4; P<0.0001). BA-CA values of PH patients were higher by 1.24 years in normal weight (P<0.0001), 1.80 years in overweight (P<0.01), and 1.40 years in obese (P<0.0001) subgroups of BMI z score-matched controls. Stepwise regression revealed that predictors of blood pressure status from normotension through prehypertension stages 1 and 2 of hypertension were BA-CA (beta=0.530; P<0.0.001), height (beta=-0.379; P<0.01), and CA (beta=0.298; P<0.05; R(2)=0.43). In conclusion, irrespective of BMI, advanced biological maturation should be considered as an independent marker for the development of hypertension.

Entities:  

Mesh:

Year:  2009        PMID: 19841285     DOI: 10.1161/HYPERTENSIONAHA.109.139949

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  Primary hypertension in childhood.

Authors:  Barbara S Bucher; Alessandra Ferrarini; Nico Weber; Marina Bullo; Mario G Bianchetti; Giacomo D Simonetti
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

2.  Accelerated growth without prepubertal obesity in nutritionally programmed microswine offspring.

Authors:  E A DuPriest; P Kupfer; B Lin; K Sekiguchi; J Q Purnell; K E Saunders; T T Chatkupt; S P Bagby
Journal:  J Dev Orig Health Dis       Date:  2012-04       Impact factor: 2.401

Review 3.  Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities.

Authors:  Mieczysław Litwin; Janusz Feber; Anna Niemirska; Jacek Michałkiewicz
Journal:  Pediatr Nephrol       Date:  2015-02-28       Impact factor: 3.714

Review 4.  Why should we screen for arterial hypertension in children and adolescents?

Authors:  Mieczysław Litwin
Journal:  Pediatr Nephrol       Date:  2017-07-17       Impact factor: 3.714

5.  Factors associated with Advanced Bone Age in Overweight and Obese Children.

Authors:  Min-Su Oh; Sorina Kim; Juyeon Lee; Mu Sook Lee; Yoon-Joo Kim; Ki-Soo Kang
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-01-08

6.  Obesity, metabolic syndrome, and primary hypertension.

Authors:  Mieczysław Litwin; Zbigniew Kułaga
Journal:  Pediatr Nephrol       Date:  2020-05-09       Impact factor: 3.714

Review 7.  Primary hypertension in children and adolescents is an immuno-metabolic disease with hemodynamic consequences.

Authors:  Mieczysław Litwin; Jacek Michałkiewicz; Lidia Gackowska
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

8.  Accelerated skeletal maturation is associated with overweight and obesity as early as preschool age: a cross-sectional study.

Authors:  Dandan Ke; Dajiang Lu; Guang Cai; Jing Zhang; Xiaofei Wang; Koya Suzuki
Journal:  BMC Pediatr       Date:  2020-09-28       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.